LISAFTOCLAX
Clinical trials for LISAFTOCLAX explained in plain language.
Never miss a new study
Get alerted when new LISAFTOCLAX trials appear
Sign up with your email to follow new studies for LISAFTOCLAX, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to boost survival in aggressive leukemia
Disease control ENROLLING_BY_INVITATIONThis study tests three different chemotherapy regimens in 450 young adults (ages 15-65) with intermediate- or high-risk acute myeloid leukemia (AML). All regimens include the experimental drug lisaftoclax plus standard chemotherapies. The main goal is to see which combination lea…
Matched conditions: LISAFTOCLAX
Phase: PHASE2, PHASE3 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to improve leukemia treatment in young adults
Disease control ENROLLING_BY_INVITATIONThis clinical trial compares three different chemotherapy regimens for young adults (ages 18-65) newly diagnosed with low-risk acute myeloid leukemia (AML). One regimen includes a new drug called lisaftoclax combined with standard chemotherapy drugs. The study aims to see which c…
Matched conditions: LISAFTOCLAX
Phase: PHASE2, PHASE3 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising leukemia combo study pulled before starting
Disease control TerminatedThis study aimed to find safe doses of two experimental drugs (lisaftoclax and pelcitoclax) combined with standard FLAG chemotherapy for adults with T-cell acute lymphoblastic leukemia that returned or didn't respond to treatment. The trial was withdrawn before enrolling any part…
Matched conditions: LISAFTOCLAX
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC